Type 2 diabetes mellitus
Conditions
Interventions
Miglitol 150 mg/day
Sponsors
Hyogo college of medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Type 2 diabetes mellitus 2. Patiens are receiving 50 mg/day of sitagliptin for more than three months 3. HbA1c has changed for the worse 4. HbA1c(NGSP) is less than 10.0% more than 6.9%
Exclusion criteria
Exclusion criteria: 1. Patients with serious heart, liver, kidney diseases 2. Pregnant and/or breathbeeding, child-bearing potential women. 3. Patients who is complicated with a malignant tumor 4. Patients with severe infection, perioperative, severe injury 5. Patients who are undergoing treatment with an arufa-glucosidase inhibitor or a rapid-acting insulin secretagogue 6. Other patients whom their physicians in charge considered unsuitable for inclusion in this study a. Patients who has laparotomy or ileus b. Patients with chronic bowel diseases with malabsorption c. Patients who has the disease which is deteriorated with increase of gas in bowel d. Patients with intolerance in Lactose e. Patient with diabetic retinopathy to need photocoagulation or vitreous surgery f. Patients with serious diabetic complications including progressed neutopathy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| plasma glucose, HbA1c, GA, 1,5-AG,Peptide, active GLP-1, and body weight | — |
Countries
Japan
Contacts
Public ContactYoshiki Kusunoki
Hyogo College of Medicine Division of Diabetes, Endocrinology, and Metabolism, Department of Internal Medicine
Outcome results
None listed